CSLLY
Price
$76.77
Change
-$1.25 (-1.60%)
Updated
May 8 closing price
Capitalization
75.58B
FOLD
Price
$6.07
Change
-$0.01 (-0.16%)
Updated
May 9, 02:27 PM (EDT)
Capitalization
1.87B
83 days until earnings call
Ad is loading...

CSLLY vs FOLD

Header iconCSLLY vs FOLD Comparison
Open Charts CSLLY vs FOLDBanner chart's image
CSL
Price$76.77
Change-$1.25 (-1.60%)
Volume$74.41K
Capitalization75.58B
Amicus Therapeutics
Price$6.07
Change-$0.01 (-0.16%)
Volume$9.43K
Capitalization1.87B
CSLLY vs FOLD Comparison Chart
Loading...
CSLLY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
FOLD
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CSLLY vs. FOLD commentary
May 09, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CSLLY is a Hold and FOLD is a Buy.

Ad is loading...
COMPARISON
Comparison
May 09, 2025
Stock price -- (CSLLY: $76.77 vs. FOLD: $6.08)
Brand notoriety: CSLLY and FOLD are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CSLLY: 68% vs. FOLD: 239%
Market capitalization -- CSLLY: $75.58B vs. FOLD: $1.87B
CSLLY [@Biotechnology] is valued at $75.58B. FOLD’s [@Biotechnology] market capitalization is $1.87B. The market cap for tickers in the [@Biotechnology] industry ranges from $301.75B to $0. The average market capitalization across the [@Biotechnology] industry is $2.17B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CSLLY’s FA Score shows that 1 FA rating(s) are green whileFOLD’s FA Score has 0 green FA rating(s).

  • CSLLY’s FA Score: 1 green, 4 red.
  • FOLD’s FA Score: 0 green, 5 red.
According to our system of comparison, CSLLY is a better buy in the long-term than FOLD.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CSLLY’s TA Score shows that 5 TA indicator(s) are bullish while FOLD’s TA Score has 4 bullish TA indicator(s).

  • CSLLY’s TA Score: 5 bullish, 5 bearish.
  • FOLD’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, CSLLY is a better buy in the short-term than FOLD.

Price Growth

CSLLY (@Biotechnology) experienced а -4.63% price change this week, while FOLD (@Biotechnology) price change was -8.98% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -5.07%. For the same industry, the average monthly price growth was +11.11%, and the average quarterly price growth was -13.36%.

Reported Earning Dates

FOLD is expected to report earnings on Jul 31, 2025.

Industries' Descriptions

@Biotechnology (-5.07% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CSLLY($75.6B) has a higher market cap than FOLD($1.87B). CSLLY YTD gains are higher at: -11.599 vs. FOLD (-35.456). CSLLY has higher annual earnings (EBITDA): 4.73B vs. FOLD (29.4M). CSLLY has more cash in the bank: 1.52B vs. FOLD (250M). FOLD has less debt than CSLLY: FOLD (444M) vs CSLLY (12B). CSLLY has higher revenues than FOLD: CSLLY (14.7B) vs FOLD (528M).
CSLLYFOLDCSLLY / FOLD
Capitalization75.6B1.87B4,038%
EBITDA4.73B29.4M16,099%
Gain YTD-11.599-35.45633%
P/E Ratio29.70N/A-
Revenue14.7B528M2,784%
Total Cash1.52B250M610%
Total Debt12B444M2,703%
FUNDAMENTALS RATINGS
CSLLY vs FOLD: Fundamental Ratings
CSLLY
FOLD
OUTLOOK RATING
1..100
177
VALUATION
overvalued / fair valued / undervalued
1..100
2
Undervalued
68
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
5493
PRICE GROWTH RATING
1..100
5891
P/E GROWTH RATING
1..100
69100
SEASONALITY SCORE
1..100
5034

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

CSLLY's Valuation (2) in the null industry is significantly better than the same rating for FOLD (68) in the Biotechnology industry. This means that CSLLY’s stock grew significantly faster than FOLD’s over the last 12 months.

CSLLY's Profit vs Risk Rating (100) in the null industry is in the same range as FOLD (100) in the Biotechnology industry. This means that CSLLY’s stock grew similarly to FOLD’s over the last 12 months.

CSLLY's SMR Rating (54) in the null industry is somewhat better than the same rating for FOLD (93) in the Biotechnology industry. This means that CSLLY’s stock grew somewhat faster than FOLD’s over the last 12 months.

CSLLY's Price Growth Rating (58) in the null industry is somewhat better than the same rating for FOLD (91) in the Biotechnology industry. This means that CSLLY’s stock grew somewhat faster than FOLD’s over the last 12 months.

CSLLY's P/E Growth Rating (69) in the null industry is in the same range as FOLD (100) in the Biotechnology industry. This means that CSLLY’s stock grew similarly to FOLD’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CSLLYFOLD
RSI
ODDS (%)
Bearish Trend 1 day ago
62%
Bullish Trend 1 day ago
68%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
57%
Bullish Trend 1 day ago
69%
Momentum
ODDS (%)
Bearish Trend 1 day ago
66%
Bearish Trend 1 day ago
83%
MACD
ODDS (%)
Bullish Trend 1 day ago
55%
Bearish Trend 1 day ago
88%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
64%
Bearish Trend 1 day ago
79%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
50%
Bearish Trend 1 day ago
77%
Advances
ODDS (%)
Bullish Trend 5 days ago
51%
Bullish Trend 10 days ago
70%
Declines
ODDS (%)
Bearish Trend 1 day ago
64%
Bearish Trend 1 day ago
78%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
50%
Bullish Trend 3 days ago
70%
Aroon
ODDS (%)
Bullish Trend 1 day ago
52%
Bearish Trend 1 day ago
78%
View a ticker or compare two or three
Ad is loading...
CSLLY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
FOLD
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
PIGDX15.63N/A
N/A
Federated Hermes International Growth IS
VRKSX10.78N/A
N/A
Virtus KAR Small-Mid Cap Growth R6
PRIDX66.75N/A
N/A
T. Rowe Price International Discovery
MGFLX9.25N/A
N/A
MassMutual Global Adm
BMSVX13.61N/A
N/A
MFS Blended Research Mid Cap Eq R4

CSLLY and

Correlation & Price change

A.I.dvisor indicates that over the last year, CSLLY has been loosely correlated with ADPT. These tickers have moved in lockstep 34% of the time. This A.I.-generated data suggests there is some statistical probability that if CSLLY jumps, then ADPT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CSLLY
1D Price
Change %
CSLLY100%
-1.60%
ADPT - CSLLY
34%
Loosely correlated
+5.22%
RXRX - CSLLY
34%
Loosely correlated
+4.77%
VIR - CSLLY
33%
Poorly correlated
-3.57%
FOLD - CSLLY
33%
Poorly correlated
-0.16%
CDXS - CSLLY
33%
Poorly correlated
+7.89%
More